eFoodSafety (EFSF)

PLEASE NOTE THAT THIS IS SPAM, and there is NO EVIDENCE that the author of this message is affiliated with any of the parties he claims to be or represent.

From: Equities Magazine <info@equities-magazine-online.com>
Date: 19-May-2006 05:01
Subject: News Alert: EPA approves EFSF Avian Flu Breakthrough

	Ground Floor Profit Opportunity from Konrad Kuhn, Editor and Publisher of The KonLin Letter The global spread of avian flu has become the most threatening health crisis in modern times. Billions will be spent in the war against this disease. This may be the one breakthrough that the world has been waiting for...a weapon that eradicates the virus, before it spreads. ...Photo courtesy NASA/JPL-Caltech ... Feds Approve Breakthrough for Avian Flu Crisis Breaking news: EPA approves eFoodSafety Big Six Plus germicidal (Citroxin), a non-toxic spray that kills bird flu virus surrogate! Non-toxic formula proven safe for broadscale uses. Human trials are now underway to test efficacy in infected patients for Influenza A and B. Agricultural use could soon stop worldwide bird flu pandemic. The official trials and approvals are complete! eFoodSafety's Big Six Plus germicidal formula is now ready to attack the global spread of Avian Flu virus! Tests prove it is 100% effective killing lab virus. It is completely non-toxic to humans and livestock. Recent EPA approval* opened the door to worldwide market possibilities. All this while eFoodSafety stock (OTC BB: EFSF) is selling at a fraction of its long-term potential! I'm telling my readers to load up on EFSF right now! Once news of the EPA approval becomes widely known, the stock could go ballistic! This virus has already surpassed $10 billion in its global impact! Company: eFoodSafety Symbol: EFSF First Target: $2 Strategy: Buy and hold for sell signal from The KonLin Letter Recommendation: Immediate BUY NOW! This is a high risk investment suitable only for aggressive investors. Please limit your investment to an amount you are comfortable putting at risk for loss. AP Photo Since 1997 when Hong Kong officials reported the H5N1 viral outbreak of avian (bird) flu, 151 million domestic birds have died or been destroyed as the result of this killer disease. The loss to agriculture now tops $10 billion and efforts to contain the disease with quarantines and culling of flocks have apparently failed. EFSF investors could see fortunes made as the rush gets underway to contain and stop bird flu. Can you imagine the revenue and profit from a product with this kind of potential? Since EPA approval has already been announced, I anticipate that eFoodSafety stock (EFSF) will not stay at today's share price for very long! You must consider this opportunity now! *EPA Registration No. 82723-1 Dear Profit-Seeking Investor: ——There's a lot at stake here so let me start with the news that could create a fortune in profits for you very shortly. ——I anticipate you could see a quick 2- to 3-fold leap off today's EFSF share prices following news that eFoodSafety has received EPA approval for its non-toxic Big Six Plus germicidal. ——This has been the key news the company has been waiting for…news that will finally open the doors to a global market for an environmentally safe, non-toxic answer to the bird flu crisis. ——The profit potential for investors is simply enormous. ——My first upside target of $2 puts EFSF in 670% gain potential. ——My second target could be so explosive, it might easily blow past a ten-bagger! I'll be publishing my forecasts and sell signals in The KonLin Letter. ——What's driving this forecast is that eFoodSafety now has its non-toxic anti-viral formula ready for global distribution. ——Now that it's received EPA approval, eFoodSafety Big Six Plus germicidal could quickly be disseminated worldwide, used to combat one of the most urgent health crises in human history, bird flu. ——Let me begin with a quick review of the toll that bird flu has taken thus far. Since its outbreak… 151 million domestic birds have died or been killed, $10 billion has been lost in agricultural economies, and sadly, 63 people have died even before the viral mutation that World Health Organization officials are saying would trigger a global pandemic of Biblical proportions. ——As horrendous as these data are, here is the figure that staggers the imagination. ——At present, about 50% of human patients who contract avian flu could die from the disease, creating a lethal risk of 180-300 million human deaths according to one highly regarded researcher. ——It's that serious. Ira Longini, from Emory University's Department of Biostatistics demonstrated the need for an effective, non-toxic weapon to stop the spread of disease using data obtained from an epidemic simulation over 5,625 square kilometers of rural Thailand. ——Longini reports, "You have two to three weeks, if it starts in a rural area, to contain the disease."  Longini goes on to say, "With a reasonably small stockpile of antiviral prophylaxis, you can contain it with a high probability." ——Please note the phrase: "antiviral prophylaxis." ——Prophylaxis means applying the remedy before the cure. Longini's assessment brings home the importance of a response like what may be possible with the non-toxic eFoodSafety Big Six Plus formula. This is exactly the use for which Big Six Plus germicidal is intended. ——I can imagine the stampede of countries seeking supplies of Big Six Plus to clean up bird flu breakouts or stop them from occuring in the first place. ——Is that going to happen? It's not guaranteed, but I for one do not want to be on the sidelines should this stampede get started. I own this stock myself and have made it my #1 stock pick for 2006. My subscribers are also ready and you could be too. ——Just look at how much America will spend…with no outbreak yet on our soil! $3.8 billion has been approved for combating bird flu in America! ——In November last year, President Bush proposed a whopping $7.1 billion budget to prevent the spread of bird flu to America. By Christmas, Congress had approved $3.8 billion of that request. ——Worldwide, you can anticipate that billions more will be spent attempting to stop bird flu from spreading further. ——When that kind of money is thrown at a problem of this magnitude, fortunes will be made, of that you can be certain. What's more, further tests suggest that a similar eFoodSafety formula can be used as an oral treatment for influenza patients! Human trials are already underway! ——Clinical trials at one of America's top pharmaceutical testing laboratories, Bucks County Clinical Research, are being conducted to show that eFoodSafety's Citroxin O2 germicidal formula can kill influenza A & B virus in vivo. (Since no patients can be tested with bird flu, the efficacy against bird flu virus will be inferred.) ——This is the same research lab that routinely tests for major pharmaceutical companies like Roche, Bristol Myers and others. There's even evidence that the germicidal formula could lead to an effective therapy for the common cold! Wouldn't that be nice...and profitable! ——In agricultural applications, Big Six Plus can be sprayed almost anywhere that bird flu is found…in chicken coops, poultry feed, nesting areas, food processing areas, etc. It's even being considered as an additive to poultry feed for prevention or treatment of disease. ——So why is eFoodSafety's product not being sprayed from airplanes right now? Good question. Now that the EPA has signed it off as non-toxic, it may well come to that! ——After all...something must be used to stop bird flu…and this could be it! Big Six Plus is proven effective…proven safe…and ready for global sales! It's non-toxic to humans and animals, can be used almost anywhere. And it's devastating to a long list of pathogens such as these nasty bugs: It eradicates black mold…the destroyer of homes! ——eFoodSafety has been selling the Citroxin cleaner for its proven, 100% effectiveness at wiping out the black mold (stachybotrys chartarum) overrunning hurricane-ravaged areas of the South. Unlike the toxic, marginally effective alternatives, Citroxin can be sprayed cost-effectively without immediate or lasting impact on humans, animals or the environment. I expect significant sales from this product in the coming year. It sanitizes food, prep surfaces, restaurants, hospitals and more destroying the EPA's 6 worst bacterial pathogens! ——Earlier in 2005, I alerted my readers to the announcement that eFoodSafety Big Six Plus germicidal passed all tests for safely and completely eradicating the EPA's six most dangerous bacterial pathogens: 1.    e-coli 2.    listeria 3.    pseudomonoas 4.    salmonella 5.    staphylococcus 6.    streptococcus ——Big Six Plus is proven completely effective when used on hard and porous surfaces making it highly desirable for routine use in hospitals, kitchens, food storage areas, and many more locations where disease can be spread. I expect huge sales from this product line. ——Tests also prove that it's 100% safe to spray and use around animals, food and humans, largely because the formula is comprised of nothing but food-safe components, previously approved by the FDA and EPA! ——This has created an incredible buying opportunity for EFSF! Since the market has completely missed its latest announcement, you could make a fortune off eFoodSafety stock (EFSF) that you buy today. ——Last September, rumors of a breakthrough appear to have triggered a 24-hour, 214% share price explosion in EFSF stock. (9/12/05)...which are poised for tremendous share price growth as the company is moving toward fulfillment of its stated objectives. Now that rumors have been verified, EFSF has become an urgent "Buy Now" opportunity! ——I would not wait to make your move. I firmly believe that eFoodSafety could quickly skyrocket once this recently announced news reaches market ears. ——That's not all… ——eFoodSafety has more products in the pipeline, some already generating revenue that could make the company hugely profitable as early as this year! And most important, eFoodSafety is about to achieve positive cash flow! ——It's rare that an investor can find a ground-floor opportunity with explosive growth potential that has already established positive fundamentals. ——eFoodSafety hit this landmark early this year, which is why I'm urging investors to move quickly on its stock (EFSF). This buying opportunity can't last much longer! ——Here are a few of the products, in addition to Big Six Plus germicide, that are carrying eFoodSafety into the future...and could be featured in coming news releases: Talsyn™ CI/bid Scar Cream The most efficacious scar cream on the market today, entering a $4 billion market. ——Talsyn is effective in the treatment of new and old scars and is particularly promising to the cosmetic surgery segment where 9.2 million procedures are performed annually. ——Talsyn also works to reduce old scars by an average of 62% over an 8-9 week treatment regimen. Available only through a physician, the product's acceptance in surgery and clinics is soaring making it a potential huge money maker in 2006. Cinnergen™ non-prescription diabetes product Sales are already surpassing expectations on this important new product. ——Diabetes is becoming one of the fastest growing chronic health problems in America's aging population. It's currently a $132 billion market . ——Cinnergen encapsulates a proven effective naturally occurring compound found in common cinnamon that can supplement subscription diabetes medications and help decrease medication needs in type 2 diabetic and borderline patients. ——Cinnergen can also forestall diabetes onset in at-risk patients. Distribution is already underway at Drugstore.com and Richard's Whole Foods. Expect more in the works for major retail drug chains. Trimmendous™ weight loss aid Staking a claim on a $33 billion market with a promising new weight-loss therapy that is both compelling and unique. ——This product is an effedrine-free weight loss product that is specifically formulated for a two-dose regimen, one for morning use and one for pre-bedtime use. ——Trimmendous improves metabolism and lifts energy levels without using risky stimulants. This product enters a huge weight loss marketplace that, though crowded with claims, has unique selling and performance benefits that could readily capture a significant share of that market. ——As progress moves forward, I expect even greater gains with EFSF that I will forecast and follow for readers of The KonLin Letter. Step ahead of the investing crowd by following the picks and forecasts you receive in The KonLin Letter. ——If stocks like EFSF have a place in your portfolio (along with a carefully researched and analyzed selection of less speculative, growth-oriented stocks), I urge you to visit my website to learn how you can receive these recommendations on a monthly basis. All risk-free of course! Here's where you can get 5 more high-profit-potential stock picks like EFSF every month of the year…with a money-back guarantee as well! ——The KonLin Letter is a recognized authority on finding and recommending low-priced stocks with great profit-making potential. It has become one of Wall Street's leading investment newsletters and ranked among the best performing in the nation. ——Each month, subscribers receive 5 new low-priced stock selections, plus a featured stock of the month, reviews of 30-35 different stocks, plus technical indicators for market timing plays. ——If you want to learn more, here's where to find a recent sample of the letter that subscribers receive! ——Visit The KonLin Letter website at: http://www.konlin.com/  Yours for Profitable Investing Konrad Kuhn, Publisher The KonLin Letter Company: eFoodSafety.com, Inc. Symbol: EFSF First Target: $2 Strategy: Buy and hold for sell signal from The KonLin Letter Recommendation: Immediate BUY NOW! This is a high risk investment suitable only for aggressive investors. Please limit your investment to an amount you are comfortable putting at risk for loss. ——P.S. Regular readers of The KonLin Letter know I do not make timing forecasts for buying and selling my picks. When we see value, we recommend a buy. And when it comes time to sell, we pull the trigger and take our profits or losses. ——That's why a subscription to The KonLin Letter can be a valuable tool for keeping your portfolio well in the black and well ahead of the investing masses. ——On the horizon: ——It obliterates Anthrax spores on hard and porous surfaces ——eFoodSafety's anthrax sporicidal also meets all EPA protocol guidelines for a 100% kill of the surrogate organisms used for the testing against anthrax. EPA registration is underway and should be approved yet this year. With this product, the bio-terror threat of weaponized anthrax could be completely neutered. ——Also... ——Watch for an announcement soon about an exciting new eFoodSafety skin care product that is reported to be better than the wildly popular "Proactiv™" line of products. If this pans out as I think it will, it could be a tremendous announcement for investors! This stock profile should be viewed as an advertisement. In order to enhance public awareness of eFood Safety, Inc. and its securities through the distribution of this report, Level Marketing was provided a budget in the amount of 25,000 USD. Level Marketing applied this budget to cover costs associated with printing and distribution of this report and will retain any excess funds as profit. The Konlin Letter and Konrad Kuhn may receive additional revenue, the amount of which cannot be determined to any degree of certainty, from sales of the Arsenal of Automatic-Profit Weapons in connection with the accompanying offer. No such additional revenue, however, will be paid by Level Marketing. This publication, its publisher, and its editor do not purport to provide a complete analysis of any company's financial position, do not constitute an offer to buy or sell securities, do not purport to offer personalized investment advice, and are not registered investment advisors. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and pertinent corporate information about the company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. All the information used to compile this report was obtained from publicly-available sources believed to be reliable—nevertheless, the publisher cannot guarantee the accuracy or completeness of this information. The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continual growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the featured company notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the company's actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for the company's products and services, the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures, etc. Disclaimer: Some statements may contain so-called "forward- looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made herein. These forward-looking statements are not historical facts, but reflect current expectations, estimates and projections. No assurance is given that these estimates, expectations or projections will be achieved. Many factors could cause actual results to differ. Investors should consult with their investment advisor, attorneys and other professionals concerning any stock transaction. Equities Magazine has relied upon information supplied by its customers, which it believes to be reliable; however, such reliability cannot be guaranteed. Equities Magazine makes no representations as to the accuracy, timeliness or completeness of the information contained in any such advertisement and disclaims any and all liability relating thereto. Equities Magazine is not responsible for any claims made by the companies advertised herein. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead Equities Magazine urges you to conduct a complete and independent investigation of the respective companies and consider of all pertinent risks. Equities Magazine does not offer such advice or analysis, and Equities Magazine further urges you to consult your own independent tax, business, financial and investment advisors. Equities Magazine has been paid $8,000 by Zacks for distribution of this press release.

Equities Magazine · 2118 Wilshire Blvd. #722 · Santa Monica, CA 90403